Dolutegravir, abacavir, and lamivudine

Action and Spectrum

Drug Interaction

Adverse Reaction

Adverse drug reactions:    

Frequency Defined  

1-10%  

Decreased neutrophils   

Increased AST   

Headache   

Fatigue  

Lipase   

Hyperglycemia   

Creatinine kinase   

Insomnia  

Increased ALT  

Depression  

<1%  

Dizziness  

Abnormal dreams  

Nausea  

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pregnancy warnings:    
AU TGA pregnancy category: B3
US FDA pregnancy category: Not assigned. 

Lactation: 

Excreted into human milk is known  

Pregnancy Categories:       

• Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester       
• Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women       
• Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women       
• Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits       
• Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women       
• Category N: There is no data available for the drug under this category      

Pharmacology

Adminstartion

Patient Information Leaflet

Patient Information Leaflet    

Generic Name: Dolutegravir, abacavir, and lamivudine 

Why do we use Dolutegravir, abacavir, and lamivudine? 

Dolutegravir, abacavir, and lamivudine belong to the class of Antivirals help to treat HIV-1 Infection.